Lancashire and South Cumbria
Formulary
Formulary
4 Central nervous system
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
04-02-01 Second-Generation Antipsychotic Drugs
CSM advice: Second-generation (atypical) antipsychotics and increased risk of stroke–see BNF
| Amisulpride |
|
Formulary
|
Tablets 50mg, 200mg, 400mg |
 LSCMMG: Shared care guideline |
|
| Aripiprazole Abilify® |
|
Formulary
|
Tablets 5mg,10mg,15mg, 30mg |
LSCMMG: Shared care guideline NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years NICE TA292: Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder |
|
|
| Cariprazine Reagila® |
|
Formulary
|
Tablets 1.5mg, 3mg, 4.5mg, 6mg |
 LSCFT - Cariprazine medicine request form LSCMMG: Shared care guideline |
|
|
| Clozapine |
|
Formulary
|
Injection LSCFT use only
|
|
LSCFT - Clozapine injection medication request form |
|
| Clozapine Clozaril® |
|
Formulary
|
| Tablets 25mg, 100mg Consultant psychiatrist initiation only Patients must be registered with the Clozapine Patient Monitoring Service (CPMS) |
|
MHRA: Clozapine and other antipsychotics: monitoring blood concentrations for toxicity MHRA: Clozapine: reminder of potentially fatal risk of intestinal obstruction, faecal impaction, and paralytic ileus |
|
|
| Clozapine Denzapine® |
|
Formulary
|
| Liquid 100mg/5mL Consultant psychiatrist initiation only Patients must be registered with the Denzapine Patient Monitoring Service |
|
MHRA: Clozapine and other antipsychotics: monitoring blood concentrations for toxicity MHRA: Clozapine: reminder of potentially fatal risk of intestinal obstruction, faecal impaction, and paralytic ileus |
|
|
| Lurasidone Latuda® |
|
Formulary
|
Tablets 18.5mg, 37mg, 74mg LSCFT initiated only |
|
LSCFT - Lurasidone medicine request form |
|
|
| Olanzapine |
|
Formulary
|
Tablets 2.5mg, 5mg, 7.5mg, 10mg, 15mg |
|
LSCMMG: Shared care guideline |
|
|
| Quetiapine |
|
Formulary
|
Tablets 25mg, 100mg, 150mg, 200mg, 300mg
LSCFT initiated only |
|
LSCFT - Quetiapine XL medicine request form LSCMMG: Shared care guideline |
|
|
| Risperidone |
|
Formulary
|
Tablets 500micrograms, 1mg, 2mg, 3mg |
|
LSCMMG: Shared care guideline |
|
|
Links
- Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years (NICE TA 213)
- Bipolar disorder (children) - aripiprazole (NICE TA292)
- LSCFT - Cariprazine medicine request form
- LSCFT - Clozapine injection medication request form
- LSCFT - Lurasidone medicine request form
- LSCFT - Quetiapine XL medicine request form
- LSCMMG SCG antipsychotics
- LSCMMG SCG antipsychotics
- LSCMMG SCG Antipsychotics
- LSCMMG SCG Antipsychotics
- LSCMMG SCG Antipsychotics
- LSCMMG SCG Antipsychotics
- LSCMMG: Dementia medicine prescribing information sheet
- LSCMMG: Management of Behavioural and Psychological Symptoms of Dementia (BPSD) in Primary and Secondary Care
- LSCMMG: Management of Behavioural and Psychological Symptoms of Dementia (BPSD). Summary document for Primary Care
- LSCMMG: Shared care guideline
- LSCMMG: Shared care guideline
- LSCMMG: Shared care guideline
- LSCMMG: Shared care guideline
- LSCMMG: Shared care guideline
- LSCMMG: Shared care guideline
- MHRA Drug Safety Update Aug 2020: Clozapine and other antipsychotics: monitoring blood concentrations for toxicity
- MHRA Drug Safety Update Aug 2020: Clozapine and other antipsychotics: monitoring blood concentrations for toxicity
- MHRA Drug Safety Update Aug 2020: Clozapine and other antipsychotics: monitoring blood concentrations for toxicity
- MHRA Drug Safety Update December 2021: Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium
- MHRA Drug Safety Update December 2021: Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium
- MHRA Drug Safety Update Oct 2017: Clozapine: reminder of potentially fatal risk of intestinal obstruction, faecal impaction, and paralytic ileus
- MHRA Drug Safety Update Oct 2017: Clozapine: reminder of potentially fatal risk of intestinal obstruction, faecal impaction, and paralytic ileus
- MHRA Drug Safety Update Oct 2017: Clozapine: reminder of potentially fatal risk of intestinal obstruction, faecal impaction, and paralytic ileus
- MHRA: Clozapine and other antipsychotics: monitoring blood concentrations for toxicity
- MHRA: Clozapine and other antipsychotics: monitoring blood concentrations for toxicity
- MHRA: Clozapine: reminder of potentially fatal risk of intestinal obstruction, faecal impaction, and paralytic ileus
- MHRA: Clozapine: reminder of potentially fatal risk of intestinal obstruction, faecal impaction, and paralytic ileus
- MHRA: Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium
- MHRA: Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium
- NICE CG103: Delirium: prevention, diagnosis and management
- NICE CG178 Psychosis and schizophrenia in adults: prevention and management
- NICE Evidence summary: Quetiapine for generalised anxiety disorder
- NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years
- NICE TA292: Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder